JANX
Janux Therapeutics, Inc.
There isn't enough reported data to score JANX yet.
JANX Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Under pressure | |
| Under pressure | |
| Unavailable |
JANX's revenue is currently strong, but its profitability and cash flow are under pressure. There isn't enough data to rate its balance sheet.
JANX PE Valuation
JANX has no meaningful PE right now: it lost money over the past year.
JANX Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses growing | |
| Strong decline | |
| -- | |
| Limited | |
| Low |
Analysts expect JANX's losses to grow, with revenue declining. However, they disagree widely on these estimates.
JANX Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$1.59 | +$0.09 |
| Q2 2026 | -$1.64 | +$0.16 |
| Q1 2026 | -$1.84 | -$0.48 |
| Q4 2025 | -$1.83 | -$0.55 |
| Q3 2025 | -$1.68 | -$0.53 |
| Q2 2025 | -$1.80 | -$0.91 |
| Q1 2025 | -$1.36 | -$0.16 |
| Q4 2024 | -$1.28 | +$0.04 |
JANX lost $1.59 per share over the past year, about the same as its loss the year before.
JANX Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $9.3M | -7.1% |
| Q3 2025 | $10M | +2178% |
| Q3 2024 | $439K | -83% |
| Q2 2024 | $8.9M | +742% |
| Q1 2024 | $1.3M | -39% |
| Q4 2023 | $2.5M | -13% |
| Q3 2023 | $2.5M | +39% |
| Q2 2023 | $1.1M | -55% |
JANX's revenue is growing: $9M last quarter, down 7.1% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -337% | +16 points |
| Q2 2026 | -309% | N/A |
| Q1 2026 | -917% | N/A |
| Q3 2025 | -353% | +7812 points |
| Q3 2024 | -8164% | -7536 points |
| Q2 2024 | -155% | +1808 points |
| Q1 2024 | -1610% | -620 points |
| Q4 2023 | -656% | -14 points |
JANX's operating margin was −337% last quarter, up 7828 points from the same quarter a year ago.
JANX Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$25.2M | -$12.2M |
| Q2 2026 | $12.3M | +$36.6M |
| Q1 2026 | -$12.6M | +$4.8M |
| Q4 2025 | -$28.6M | -$11.9M |
| Q3 2025 | -$12.9M | -$10.7M |
| Q2 2025 | -$24.3M | -$14.2M |
| Q1 2025 | -$17.4M | -$2.4M |
| Q4 2024 | -$16.8M | -$6.4M |
JANX has burned cash in almost every quarter: −$54M over the past year, against −$71M the year before.
JANX Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.2% | +153K shares |
| 1 year | +1.7% | +1.1M shares |
| 3 years | +38% | +17.4M shares |
| 5 years | +529% | +53.1M shares |
| Available history | +406% | +50.6M shares |
JANX has 63M diluted shares, up 1.7% from a year ago.
| Quarter | Spent |
|---|---|
| Q1 2021 | — |
| Q4 2020 | — |
| Q3 2020 | — |
| Q2 2020 | — |
| Q1 2020 | — |
JANX Net Leverage
JANX's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
JANX Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 35.3 | Neutral |
| Stochastic | 34.0 | Neutral |
JANX's weekly RSI is 35 (neutral) and its Stochastic is 34 (neutral).
JANX PE vs Healthcare Sector
JANX has no meaningful PE right now: it lost money over the past year.
JANX Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $16.4 | 30% below |
| 20 week MA | $16.6 | 31% below |
| 50 week MA | $15.1 | 24% below |
| 100 week MA | $22.7 | 49% below |
| 200 week MA | $24.7 | 53% below |
JANX is in a downtrend: it's below all five of its weekly moving averages, and 53% below its 200-week average.
JANX Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $25.2 | $21.4 | -15% |
| 2022 | $21.4 | $11.9 | -45% |
| 2023 | $11.9 | $10.7 | -9.5% |
| 2024 | $10.7 | $54.1 | +404% |
| 2025 | $54.1 | $14.3 | -74% |
| 2026 YTD | $14.3 | $11.5 | -19% |
JANX's yearly returns have swung widely, from +404% in 2024 to −74% in 2025. It's down 19% so far in 2026.